Genmab A/S (NASDAQ:GMAB) Shares Acquired by Legacy Wealth Asset Management LLC

Legacy Wealth Asset Management LLC raised its stake in Genmab A/S (NASDAQ:GMAB - Free Report) by 36.7% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 49,367 shares of the company's stock after acquiring an additional 13,246 shares during the quarter. Legacy Wealth Asset Management LLC's holdings in Genmab A/S were worth $967,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of GMAB. Deep Track Capital LP purchased a new position in shares of Genmab A/S in the 4th quarter valued at about $41,740,000. Brandywine Global Investment Management LLC purchased a new stake in shares of Genmab A/S in the fourth quarter valued at approximately $33,804,000. Two Sigma Advisers LP grew its stake in Genmab A/S by 168.8% in the 4th quarter. Two Sigma Advisers LP now owns 1,653,500 shares of the company's stock valued at $34,509,000 after acquiring an additional 1,038,400 shares during the period. Two Sigma Investments LP grew its stake in Genmab A/S by 122.2% in the 4th quarter. Two Sigma Investments LP now owns 1,706,364 shares of the company's stock valued at $35,612,000 after acquiring an additional 938,455 shares during the period. Finally, Marshall Wace LLP increased its holdings in Genmab A/S by 162.2% in the 4th quarter. Marshall Wace LLP now owns 1,122,296 shares of the company's stock worth $23,422,000 after acquiring an additional 694,243 shares in the last quarter. Hedge funds and other institutional investors own 7.07% of the company's stock.

Genmab A/S Trading Down 1.9%

GMAB stock traded down $0.42 during midday trading on Tuesday, hitting $21.35. 1,129,495 shares of the company's stock were exchanged, compared to its average volume of 1,145,579. Genmab A/S has a 1-year low of $17.24 and a 1-year high of $28.96. The business has a 50-day simple moving average of $19.96 and a two-hundred day simple moving average of $20.63. The stock has a market capitalization of $13.69 billion, a PE ratio of 12.27, a P/E/G ratio of 2.65 and a beta of 1.04.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.23 by $0.08. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. The business had revenue of $715.00 million for the quarter, compared to the consensus estimate of $5.17 billion. As a group, research analysts expect that Genmab A/S will post 1.45 EPS for the current fiscal year.

Analyst Ratings Changes

GMAB has been the subject of a number of research reports. William Blair raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating in a research note on Tuesday, March 11th. Leerink Partners raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 target price for the company in a report on Thursday, February 13th. Sanford C. Bernstein cut shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a research report on Tuesday, April 1st. Truist Financial dropped their price objective on shares of Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a research note on Tuesday, March 11th. Finally, HC Wainwright reiterated a "buy" rating and issued a $37.00 price objective (down previously from $50.00) on shares of Genmab A/S in a report on Wednesday, April 9th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Genmab A/S has an average rating of "Moderate Buy" and a consensus target price of $39.17.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.